Esteve CDMO to Add New Production Unit in Celrà
Published: 31 Mar 2026
Author: Precedence Research
Esteve CDMO, a global CDMO specialised in small-molecule APIs and advanced pharmaceutical intermediates, has expanded its plans for the buildout of a new production unit at its facility in Celrà, Spain. In parallel to its already-announced strategy to expand both production capacity and advanced containment capabilities unit announced to add a further 3,000-square-meter production unit to accommodate additional spray drying equipment and services with a purpose-built, high-potency containment suite.
The multi-year investment plans include a GEA Pharma-SD PSD-2 spray dryer and a new PSD-3, which is expected to be fully operational in 2027. The company expects to add up to 15 new staff when PSD-2 and PSD-3 operations are fully underway, with PSD-4 operations planned to commence later.
These investments will enhance its capability to safely and efficiently handle highly potent compounds while reinforcing its technological leadership in amorphous solid dispersion (ASD) solutions.
According to Towards Healthcare, the Pharmaceutical Intermediate CDMO market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 46.72 billion in 2026 to approximately USD 89.72 billion by 2035, representing a compound annual growth rate (CAGR) of 7.52% from 2026 to 2035. Growth of the Pharmaceutical Intermediate CDMO market is driven by increasing pharmaceutical outsourcing, rising demand for cost-efficient production, expanding drug pipelines, advancements in synthesis technologies, regulatory compliance requirements, and growing focus on specialized, high-quality intermediates manufacturing globally.
Unveiling the new ESTEVE CDMO Brand
The new ESTEVE CDMO brand was unveiled at DCAT week in New York, taking a significant step to expand its production capacity and advanced containment capabilities. It aims to establish a strong, consistent global presence, and it communicates the value that governs its corporate culture and interacts clearly and meaningfully with stakeholders.
Global Head of Commercial Operations and Strategy and Managing Director US at Esteve CDMO, Andrea Oro said Excellence is embedded in everything we do it defines our mindset and guides our actions at every stage.
President at Esteve CDMO Joan Petit stated that as our work in Girona progresses, we must remain aligned with the needs of our partners, and adding spray drying capabilities can help solve problems they face with the characteristics of development pipelines, such as stability, poor solubility, potency, and scalability.
A recent report by Towards Healthcare highlights that the Pharmaceutical Intermediate CDMO market, driven by rising outsourcing trends, increasing demand for complex intermediates, and expanding pharmaceutical pipelines, is expected to witness growth with innovation and strategic collaborations accelerating global expansion.